German Merck, Pfizer get FDA priority review for cancer drug
November 29, 2016 at 08:06 AM EST
FRANKFURT, Nov 29 (Reuters) - German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.
